Drug Trial Radar · NCT00003752
Bexarotene in Treating Patients With Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: May 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Planned (sponsor's estimate)
Start
Oct 1998
Primary completion
Not stated
Study completion Mar 2003
Sponsor
- Lead sponsor
- Ligand PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 25, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase II trial to study the effectiveness of bexarotene in treating patients who have metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
bexaroteneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama Comprehensive Cancer Center
Birmingham, Alabama
Arizona Cancer Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
USC/Norris Comprehensive Cancer Center
Los Angeles, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California
Beckman Research Institute, City of Hope
Los Angeles, California
Kaiser Permanente-Southern California Permanente Medical Group
San Diego, California
UCSF Cancer Center and Cancer Research Institute
San Francisco, California
Yale Comprehensive Cancer Center
New Haven, Connecticut
Vincent T. Lombardi Cancer Research Center, Georgetown University
Washington D.C., District of Columbia
Baptist Regional Cancer Institute - Jacksonville
Jacksonville, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida
Sylvester Cancer Center, University of Miami
Miami, Florida
Cancer Research Center of Hawaii
Honolulu, Hawaii
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois
Louisiana State University School of Medicine
New Orleans, Louisiana
Dana-Farber Cancer Institute
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Michigan State University
East Lansing, Michigan
University of Minnesota
Minneapolis, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Memorial Sloan-Kettering Cancer Center
New York, New York
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio
Hematology Oncology Consultants Inc
Columbus, Ohio
Oregon Cancer Center at Oregon Health Sciences University
Portland, Oregon
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon-Minnie Pearl Cancer Center
Nashville, Tennessee
University of Texas - MD Anderson Cancer Center
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Cancer Center, University of Virginia HSC
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.